Q-omics provides the consensus-scored SNORD94 profile across patient tissues and cancer cell-line models. SNORD94 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, SNORD94 is differentially expressed in 12, with the highest sampling consensus in COAD. Additionally, SNORD94 RNA expression shows 18,847 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KIRC, COAD, and UVM as cancer lineages where SNORD94 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SNORD94 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SNORD94 survival associations across molecular data types. SNORD94 RNA expression shows survival associations in the most cancer types (20). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SNORD94 RNA expression–survival associations across cancer types. High SNORD94 expression shows unfavorable associations in KIRC, COAD, ACC, UVM and THCA, but favorable associations in UCS. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for SNORD94 RNA expression.
This table summarizes SNORD94 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for SNORD94. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SNORD94 shows higher tumor expression in COAD, KIRC, LUSC, HNSC, BLCA and LIHC. The COAD box plot shows higher SNORD94 RNA expression in tumor versus normal tissue (log2 FC = +1.288, t-test p < 0.001).
This table shows molecular features associated with SNORD94 in patient tissues and cancer cell lines. In patient samples, SNORD94 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set.
